150 related articles for article (PubMed ID: 12944569)
1. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.
Lawrence J; Mayers DL; Hullsiek KH; Collins G; Abrams DI; Reisler RB; Crane LR; Schmetter BS; Dionne TJ; Saldanha JM; Jones MC; Baxter JD;
N Engl J Med; 2003 Aug; 349(9):837-46. PubMed ID: 12944569
[TBL] [Abstract][Full Text] [Related]
2. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
Kovacs JA; Vogel S; Albert JM; Falloon J; Davey RT; Walker RE; Polis MA; Spooner K; Metcalf JA; Baseler M; Fyfe G; Lane HC
N Engl J Med; 1996 Oct; 335(18):1350-6. PubMed ID: 8857018
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
[TBL] [Abstract][Full Text] [Related]
4. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
6. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
[TBL] [Abstract][Full Text] [Related]
7. A controlled trial of zidovudine in primary human immunodeficiency virus infection.
Kinloch-De Loës S; Hirschel BJ; Hoen B; Cooper DA; Tindall B; Carr A; Saurat JH; Clumeck N; Lazzarin A; Mathiesen L
N Engl J Med; 1995 Aug; 333(7):408-13. PubMed ID: 7616989
[TBL] [Abstract][Full Text] [Related]
8. HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count.
Jaafar A; Massip P; Sandres-Sauné K; Souyris C; Pasquier C; Aquilina C; Izopet J
J Med Virol; 2004 Sep; 74(1):8-15. PubMed ID: 15258962
[TBL] [Abstract][Full Text] [Related]
9. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.
Ruiz L; Ribera E; Bonjoch A; Romeu J; Martinez-Picado J; Paredes R; Díaz M; Marfil S; Negredo E; García-Prado J; Tural C; Sirera G; Clotet B
J Infect Dis; 2003 Oct; 188(7):977-85. PubMed ID: 14513417
[TBL] [Abstract][Full Text] [Related]
10. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
11. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
13. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
[TBL] [Abstract][Full Text] [Related]
14. Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1.
Hasson H; Mantelli B; Biswas P; Malnati M; Gianotti N; Vecchi A; Nozza S; Cernuschi M; Boeri E; Clerici M; Lazzarin A; Beretta A
J Med Virol; 2007 Nov; 79(11):1640-9. PubMed ID: 17854028
[TBL] [Abstract][Full Text] [Related]
15. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
17. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
18. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA
N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228
[TBL] [Abstract][Full Text] [Related]
19. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
